Intramuscular 50mg methotrexate injection therapy for severe psoriasis: Study on effectivity and side effect
Study on Effectivity and Side Effect
DOI:
https://doi.org/10.66344/jpad.v31i4.1736Abstract
Background Psoriasis is a chronic autoimmune and inflammatory skin disease. Parenteral methotrexate has promising potential to be used as treatment choice for severe psoriasis. However, no effectivity and safety data to be used severe psoriasis. Our objective is to determine the effectivity and safety of intramuscular 50 mg methotrexate for severe psoriasis.
Methods This is a descriptive retrospective study in severe psoriasis. The data were taken from Dr. Sardjito Hospital Yogyakarta, Indonesia medical record, which fulfilled the inclusion and exclusion criteria. Subjects were previously administered with intramuscular 50 mg methotrexate injection according to the protocol. Comparative analysis is performed to determine treatment effectivity parameters consisting of psoriasis area severity index (PASI) and dermatological life quality index (DLQI) score. Side effects found in this study were analyzed descriptively.
Results 35 severe psoriasis subjects were enrolled in this study. Significant PASI and DLQI scores reduction were found during treatment protocol. PASI-75 and PASI-90 scores were achieved by 50% subject in 4th and 8th week. Severe side effect of hepatotoxicity with >2 times SGOT/SGPT upper limit level elevation was found in 2.9% subjects.
Conclusion Intramuscular 50 mg methotrexate injection can be an effective and safe treatment for severe psoriasis in a limited setting.
References
1. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012. p.197-231.
2. Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update - short version part 1 - systemic treatment. J Dtsch Dermatol Ges. 2018;16(5):645-69. [PMID: 29750443].
3. Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol. 2017;92(5):668-74. [PMID: 29166504].
4. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:1-7. [PMID: 16756666].
5. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical co-morbidities: A population-based study. JAMA Dermatol. 2013;149(10):1173-79. [PMID: 23925466].
6. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168-73. [PMID: 17922664].
7. Buj R, Aird KM. Deoxyribonucleotide triphosphate metabolism in cancer and metabolic disease. Front Endocrinol. 2018;9:1-10. [PMID: 29720963].
8. West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials. PLoS One. 2016;11(5):1-14. [PMID: 27168193].
9. Vena GA, Cassano N, Lannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag.2018;14:105-16. [PMID: 29386902].
10. Warren RB, Weatherhead SC, Smith CH, et al. British association of dermatologist guideline for the safe and effective prescribing of methotrexate for skin disease. Br J Dermatol.2016;175:23-44. [PMID: 27484275].
11. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20(11):1845–9. [PMID: 8308768].
12. Kemenkes RI, Keputusan menteri kesehatan republik Indonesia nomor HK.01.07/MENKES/659/2017 tentang formularium nasional. Departemen Kesehatan RI, Jakarta; 2017
13. Hendarwan H, Yuniar Y, Despitasari M. Kefarmasian dan alat kesehatan. In: Supriyantoro, Ardyanto TD, Wibowo DB. Harapan, Kenyataan, dan Solusi JKN dalam Rangkaian Diskusi Panel Indonesia Healthcare Forum. Lembaga Penerbit Balitbangkes, Jakarta; 2018. p.109-37.
14. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-85. [PMID: 23014338].
15. Mahler V, Diepgen T, Skudlik C, et al. Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertise. JDDG.2014;4:519-29. [PMID: 24889306].
16. Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open.2017;3:1-9. [PMID: 28123781].
17. Rademaker M, Gupta M, Andrews M, et al. The Autralasian psoriasis collaboration view on methotrexate for psoriasis in the Australasian setting. Aus J Dermatol. 2016;58(3):166-70. [PMID: 27402434].
18. Vidal D, Salleras M, Romani J, et al. Adherence of self-administered subcutaneous methotrexate in patients with chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol.2016;30(11):131-2. [PMID: 26446358].
19. Warren RB, Mrowietz U, Kiedrowski RV, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicenter, randomized, double blind, placebo controlled, phase 3 trial. Lancet. 2016;389:528-37. [PMID: 28012564].
20. Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology.2008; 216:260-70. [PMID: 18187944].
21. Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present, and future. Clin Exp Dermatol.2013;38:573-88. [PMID: 23837932].
22. Wang W, Shou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem.2018;158:502-16. [PMID: 30243154].
23. Swierkot J, Slezak R, Karpinski P, et al. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol Arch Med Wewn.2015;125(3):152-61. [PMID: 25599563]..
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Sunardi Radiono, Prasta Bayu Putra, Dyah Ayu Mira Oktarina
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
